HSP90抑制剂AT13387通过抑制DNA损伤修复、核苷酸代谢和放疗诱导的肿瘤血管生成增强头颈鳞癌移植瘤放射敏感性
该临床前研究探讨HSP90抑制剂AT13387(Onalespib)联合放疗对头颈鳞癌(HNSCC)的增敏机制。AT13387联合放疗导致G2/M期阻滞、抑制DNA修复、降低糖酵解和三羧酸循环关键代谢物及ATP水平,并减少核苷酸代谢限速代谢物。HNSCC移植瘤中联合治疗延长肿瘤再生长延迟,减少CD45和CD11b+骨髓来源细胞浸润,抑制HIF-1和SDF-1表达,从而抑制放疗诱导的血管生成。
要点
- AT13387联合放疗在HNSCC中诱导G2/M期阻滞并抑制DNA损伤修复。
- AT13387降低糖酵解、三羧酸循环代谢物、ATP及核苷酸代谢限速代谢物水平。
- 联合治疗抑制放疗诱导的肿瘤血管生成,减少骨髓来源细胞浸润。
核心结论
- AT13387通过药理抑制癌细胞代谢并与DNA损伤修复相关联,联合放疗抑制放疗诱导的血管生成,该过程参与放疗后肿瘤复发。
- 联合AT13387与放疗值得考虑开展临床试验评估。
研究设计与样本
- 研究使用HNSCC和非小细胞肺癌细胞系在体外和体内评估AT13387的放射增敏效应。
- 采用流式细胞术、免疫荧光和免疫印迹分析细胞周期变化及HSP90客户蛋白在DNA损伤修复中的作用。
- 采用液相色谱-质谱联用进行代谢分析。
- 对AT13387和放疗后切除的肿瘤进行免疫组化检查以识别放疗诱导血管生成的生物标志物。
主要发现
- AT13387联合放疗导致G2/M细胞周期阻滞并抑制DNA修复。
- 代谢谱显示AT13387降低糖酵解和三羧酸循环关键代谢物、ATP水平以及核苷酸代谢限速代谢物磷酸核糖焦磷酸和天冬氨酸。
- HNSCC移植瘤联合治疗组显示肿瘤再生长延迟增加,CD45和CD11b+骨髓来源细胞浸润减少。
- 联合治疗抑制HIF-1和SDF-1表达,从而抑制放疗诱导的血管生成。
临床怎么用
- 临床前证据提示AT13387联合放疗可能通过多机制增强HNSCC放射敏感性,值得进一步临床试验评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Recent preclinical studies suggest combining the HSP90 inhibitor AT13387 (Onalespib) with radiation (IR) against colon cancer and head and neck squamous cell carcinoma (HNSCC). These studies emphasized that AT13387 downregulates HSP90 client proteins involved in oncogenic signaling and DNA repair mechanisms as major drivers of enhanced radiosensitivity. Given the large array of client proteins HSP90 directs, we hypothesized that other key proteins or signaling pathways may be inhibited by AT13387 and contribute to enhanced radiosensitivity. Metabolomic analysis of HSP90 inhibition by AT13387 was conducted to identify metabolic biomarkers of radiosensitization and whether modulations of key proteins were involved in IR-induced tumor vasculogenesis, a process involved in tumor recurrence. METHODS AND MATERIALS: HNSCC and non-small cell lung cancer cell lines were used to evaluate the AT13387 radiosensitization effect in vitro and in vivo. Flow cytometry, immunofluorescence, and immunoblot analysis were used to evaluate cell cycle changes and HSP90 client protein's role in DNA damage repair. Metabolic analysis was performed using liquid chromatography-Mass spectrometry. Immunohistochemical examination of resected tumors post-AT13387 and IR treatment were conducted to identify biomarkers of IR-induced tumor vasculogenesis. RESULTS: In agreement with recent studies, AT13387 treatment combined with IR resulted in a G2/M cell cycle arrest and inhibited DNA repair. Metabolomic profiling indicated a decrease in key metabolites in glycolysis and tricarboxylic acid cycle by AT13387, a reduction in Adenosine 5'-triphosphate levels, and rate-limiting metabolites in nucleotide metabolism, namely phosphoribosyl diphosphate and aspartate. HNSCC xenografts treated with the combination exhibited increased tumor regrowth delay, decreased tumor infiltration of CD45 and CD11b+ bone marrow-derived cells, and inhibition of HIF-1 and SDF-1 expression, thereby inhibiting IR-induced vasculogenesis. CONCLUSIONS: AT13387 treatment resulted in pharmacologic inhibition of cancer cell metabolism that was linked to DNA damage repair. AT13387 combined with IR inhibited IR-induced vasculogenesis, a process involved in tumor recurrence postradiotherapy. Combining AT13387 with IR warrants consideration of clinical trial assessment.
引用
- Naz S, Leiker AJ, Choudhuri R, et al. Pharmacological Inhibition of HSP90 Radiosensitizes Head and Neck Squamous Cell Carcinoma Xenograft by Inhibition of DNA Damage Repair, Nucleotide Metabolism, and Radiation-Induced Tumor Vasculogenesis. Int J Radiat Oncol Biol Phys. 2021. PMID: 33838214. doi:10.1016/j.ijrobp.2021.03.048
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。